Form D · Pharmaceuticals
Anivive Lifesciences, Inc.
Long Beach, CA · CIK 0001877715
Offering snapshot reported Aug 12, 2021 · SEC filing
- Reported sold
- $44.3M Offering amount: $44.3M
- Investors reported
- 78 Form D · investor count
- Minimum accepted
- $0 Reported outside-investor minimum
- First sale
- Jul 29, 2021 As reported in this filing
What changed?
Latest filing versus its linked predecessor, where available.
No comparable changes in the displayed metrics.
Filing history
Scroll to see all columns →
| Filed | Filing type | Reported sold | Change vs linked filing | Investors | Source |
|---|---|---|---|---|---|
| Aug 12, 2021 | Initial | $44,300,424 | No comparison | 78 | SEC filing |
Offering details
- Securities
- Equity
- Exemptions
- 06b
- Duration over one year
- No
- Business combination
- No
- Sales commissions
- $0
- Finders' fees
- $0
- Form D file number
- 021-409702
Source: Form D, filed Aug 12, 2021. Minimum accepted may differ from a standard advertised minimum.
Fund connections
No confirmed ADV fund connection is available for this issuer.
People & organizations
Current and past Form D appearances. These existing records do not establish a person's current role or uniquely identify them across issuers.
| Name | Reported role |
|---|---|
| Dylan Balsz | Director, Executive |
| Robert Bishop | Director |
| David Bruyette | Director, Executive |
| Cheryl Collett | Executive |
| Lynne Doti | Director |
| Rick Haugen | Director |
| Glenn Stearns | Director |
| Scott Whitcup | Director |
Issuer details
Industry: Pharmaceuticals (See others in industry)
Address:
3250 Airflite Way Suite 400
Long Beach, CA, 90807
Long Beach, CA, 90807